OCGN
HEALTHCAREOcugen Inc
$1.46-0.04 (-2.35%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving OCGN Today?
No stock-specific AI insight has been generated for OCGN yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.64$2.73
$1.46
Fundamentals
Market Cap$493M
P/E Ratio—
EPS$-0.24
Dividend Yield—
Dividend / Share—
ROE-7.8%
Profit Margin—
Debt / Equity—
Trading
Volume15.7M
Avg Volume (10D)—
Shares Outstanding338.5M
OCGN News
22 articles- Ocugen (OCGN) Is Down 16.8% After $115M Convertible Notes Deal And Wider Q1 Losses Has The Bull Case Changed?Yahoo Finance·May 9, 2026
- Ocugen (OCGN) Upgraded to Buy: Here's WhyYahoo Finance·May 8, 2026
- Number of shareholders of Ocugen Inc – LSX:A2PSZHTradingView·May 8, 2026
- OCGN Falls on Wider Q1 Loss Despite Strong Pipeline Progress OutlookYahoo Finance·May 6, 2026
- Ocugen Q1 Earnings Call HighlightsMarketbeat·May 5, 2026
- Ocugen (OCGN) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 5, 2026
- Ocugen Provides Business Update with First Quarter 2026 Financial ResultsYahoo Finance·May 5, 2026
- Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior NotesYahoo Finance·May 5, 2026
- Ocugen Announces Private Offering of $115 Million of Convertible Senior NotesYahoo Finance·May 4, 2026
- Ocugen (OCGN) Completes Enrollment for Phase 2/3 Pivotal Trial of OCU410ST Gene TherapyYahoo Finance·May 1, 2026
- Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial ResultsYahoo Finance·Apr 29, 2026
- How The Ocugen (OCGN) Story Is Shifting With Gene Therapy Milestones And Valuation DebateYahoo Finance·Apr 26, 2026
- Ocugen to Present at April 2026 Investor and Industry ConferencesYahoo Finance·Apr 23, 2026
- Ocugen (OCGN) Valuation Check After Encouraging Phase 2 ArMaDa Results For OCU410Yahoo Finance·Apr 23, 2026
- OCGN Gene Therapy Pipeline: Key 2026-27 Catalysts AheadYahoo Finance·Apr 22, 2026
- Ocugen Stock Outlook: Valuation, Cash Runway and Dilution RiskYahoo Finance·Apr 22, 2026
- OCGN's Gene-Agnostic Strategy Could Reset Retinal TherapyYahoo Finance·Apr 22, 2026
- OCU410’s Phase 2 Gene‑Agnostic Results in Dry AMD Might Change The Case For Investing In Ocugen (OCGN)Yahoo Finance·Apr 21, 2026
- MeiraGTx (MGTX) Soars 6.8%: Is Further Upside Left in the Stock?Yahoo Finance·Apr 20, 2026
- Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated CellsBenzinga·Apr 10, 2026
- Evaluating Ocugen (OCGN) After Recent Share Price Swings And Gene Therapy ProgressYahoo Finance·Apr 5, 2026
- Ocugen (OCGN) Up 2.9% Since Last Earnings Report: Can It Continue?Yahoo Finance·Apr 3, 2026
All 22 articles loaded
Price Data
Open$1.53
Previous Close$1.49
Day High$1.53
Day Low$1.45
52 Week High$2.73
52 Week Low$0.64
52-Week Range
$0.64$2.73
$1.46
Fundamentals
Market Cap$493M
P/E Ratio—
EPS$-0.24
Dividend Yield—
Dividend / Share—
ROE-7.8%
Profit Margin—
Debt / Equity—
Trading
Volume15.7M
Avg Volume (10D)—
Shares Outstanding338.5M
About Ocugen Inc
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the development of gene therapies to cure diseases of blindness. The company is headquartered in Malvern, Pennsylvania.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—